Quarterly ResultMay 15, 2026, 04:08 PM
Annovis Bio Phase 3 AD Trial 85% Enrolled; Q1 Net Loss $(0.63)
AI Summary
Annovis Bio reported strong progress in its clinical programs for Q1 2026, with 85% enrollment in its Phase 3 Alzheimer's disease (AD) trial and 40% enrollment in its Parkinson's disease (PD) open-label extension study. The company anticipates filing a New Drug Application (NDA) for symptomatic AD in early 2027 and for disease-modifying AD in early 2028. Financially, Annovis Bio reported a net loss per share of $(0.63) for the quarter, with research and development expenses increasing to $16.7 million.
Key Highlights
- Phase 3 AD trial 85% enrolled, targeting full enrollment by summer 2026.
- PD open-label extension study 40% enrolled, targeting full enrollment by Q4 2026.
- NDA for symptomatic AD expected early 2027; disease-modifying AD in early 2028.
- Q1 2026 R&D expenses increased to $16.7 million from $5.0 million YoY.
- Q1 2026 net loss per share was $(0.63), compared to $(0.32) in Q1 2025.
- Cash and cash equivalents totaled $14.2 million as of March 31, 2026.
- Secured a U.S. patent for treating neurological injuries from brain infections.
Price Impact
More from ANVS